Get to know our clinical trials
Randomized, double-blind, multicenter, placebo-controlled Phase III trial to evaluate the efficacy and safety of trimodulin (BT588) in hospitalized adult subjects with severe community-acquired pneumonia (CAP)
THE PURPOSE OF THIS CLINICAL TRIAL IS TO TEST WHETHER TRIMODULIN (THE TRIAL DRUG) WORKS AND WHETHER IT IS SAFE TO TREAT PEOPLE WITH SEVERE COMMUNITY-ACQUIRED PNEUMONIA (CAP) WHEN GIVEN WITH THE STANDARD OF CARE. THE REFERENCE TREATMENTS REFER TO THE MOST COMMON TREATMENTS GIVEN TO PEOPLE WHO ARE HOSPITALIZED WITH CAP AND NEED MECHANICAL VENTILATION TO BREATHE.
Technical Summary
- PHASE III RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TRIMODULIN (BT588) IN HOSPITALIZED ADULT SUBJECTS WITH SEVERE COMMUNITY-ACQUIRED PNEUMONIA (CAP)
- Code EudraCT: 2022-501352-28-00
- Protocol number: 996
- Promoter: Biotest AG
- Molecule/Drug: BT588
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.